Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher

Compared to Standard Chemotherapy

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised. Seventy-four percent of patients discontinued therapy for disease progression or death, the majority of which were in the standard chemotherapy control arm.

CTI plans to submit complete study data for presentation at a major scientific conference. CTI also intends to request a pre-NDA meeting with the FDA and expects to begin submission of a rolling New Drug Application (NDA) to the FDA in early 2009.

"This positive phase II
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
(Date:9/3/2015)... and REHOVOT, Israel, Sept. 3, 2015 ... and developing innovative therapies for ear, nose, and throat ... Company,s Newport Gateway office complex to be the location ... the move by end of September and will have ... U.S. Headquarters: OticPharma, Inc. 19900 MacArthur Blvd., ...
(Date:9/2/2015)... , Sept. 2, 2015 Balloon angioplasty ... obstructed blood vessels. This report is on global ... of the market. The report comprises an elaborate ... provides overall information of various segments and sub-segments ... the overall information and data analysis of the ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5OticPharma Establishes U.S. Headquarters in Orange County, California 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
(Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director ... Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on ... expert in care for the critically injured and the development, design and operations of ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology ... test that may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed ... are often caused by HPV infections, which have a high rate of success in ...
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the ... will be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ... and 17 at the Olympia London, booth #F33 , Be the first to get ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Act (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more ... employers (1,000+ employees), according to data released from the 2014 United Benefit Advisors ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... The experts reveal that lot more funds are needed from ... deaths of children under five by two-thirds.// ,Five ... experts, whose paper is one of the series of papers ... high-level meeting hosted by the journal, UNICEF and the Norwegian ...
... drug extensively used to treat acne can cause depression. ... animals.// ,Recently, the drug- Roaccutane, which effectively ... severe side-effects like suicidal behaviour. Though the packaging of ... occurrence of such side-effects is not known.,It has not ...
... an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan ... told reporters that the drug would be priced at 40 ... "Today we join the exclusive league of MAb developers worldwide. ... she added. She also told the drug was undergoing regulatory ...
... and Kashmir has a new problem to contend with now ... there are 745 such cases in the insurgency-hit state, unofficial ... there were only two cases reported, writes Grassroots Features. The ... the infection rate among the high-risk groups (STD-infected) at 0.95 ...
... arm in a motorcycle accident. She has become the first woman to ... own nerves. ,She talked about how she used it ... able to eat in a conventional way since her accident of over ... me.” ,Very often patients fitted with high-tech prosthetic limbs ...
... A new web site at the University of California, ... will enable people from around the world// to self-report ... other cholesterol drugs. ,“This line of research ... heart disease and cholesterol are familiar with the benefits ...
Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... as either EDTA K2 or EDTA ... ions and therefore blocks the coagulation ... an EDTA anticoagulated blood sample are ... EDTA tubes are for the examination ...
Medicine Products: